This deadline has passed, but here’s another class action for you.
The Mylan Pharmaceuticals EpiPen Monopoly Class Action alleges that Mylan N.V., Mylan Pharmaceuticals Inc., and Mylan Specialty L.P. (collectively, “Mylan”) conspired with Pfizer, Inc., King Pharmaceuticals, Inc., Meridian Medical Technologies, Inc. (collectively, “Pfizer”), and Teva Pharmaceuticals USA, Inc. (“Teva”) to suppress the release of generic EpiPen products. This alleged scheme purportedly extended their monopolies over the epinephrine auto-injector market, allowing them to charge higher prices. Mylan denies any wrongdoing but has agreed to a $73.5 million settlement to resolve these claims.
Who Qualifies for a Payout in This Settlement?
You may be eligible for a payment from this settlement if you are a person or entity in the United States or its territories, possessions, or the Commonwealth of Puerto Rico that purchased EpiPen or generic EpiPen products directly from Mylan or Teva for resale between March 13, 2014, and February 6, 2025.
Is It Necessary to Provide Proof (or Proof of Purchase)?
Yes, to file a claim, you must provide valid documentation supporting your direct purchases of EpiPen or generic EpiPen products during the specified period. This documentation may include receipts, invoices, or other records demonstrating your purchases.
What Amount Can I Receive from This Settlement?
The exact amount each claimant will receive depends on the number of valid claims submitted and the volume of EpiPen or generic EpiPen products purchased during the class period. Currently, no specific payment estimates are available. The $73.5 million settlement fund will be distributed among eligible claimants after deductions for attorneys’ fees, administration costs, and other expenses as approved by the Court.
How Can I Submit My Claim?
To participate in the settlement and receive a payment, you must submit a valid Claim Form by May 29, 2025. Claims can be submitted online or by mail:
- Online Submission: Complete the Claim Form available on the official settlement website: https://epipendppsettlement.com/Home/MylanHomePage.
- Mail Submission: Download and print the Claim Form from the settlement website, then mail the completed form along with supporting documentation to the Settlement Administrator at: EpiPen Direct Purchaser-Mylan Settlement c/o A.B. Data, Ltd. P.O. Box 173113 Milwaukee, WI 53217
If you previously submitted a Claim Form during the settlement with Pfizer in this case, you do not need to submit a new Claim Form for the Mylan settlement. Your prior submission will be used for this settlement, and you have the option to provide supplemental information if desired.
Important Dates
- Claim Form Submission Deadline: May 29, 2025.
- Exclusion (Opt-Out) Deadline: April 11, 2025.
- Objection Deadline: April 11, 2025.
- Final Approval Hearing: May 29, 2025, at 1:30 p.m. Central Time at the United States District Court for the District of Kansas, 500 State Avenue, Courtroom 476, Kansas City, KS 66101.
Your Legal Rights and Options
- Submit a Claim: To receive a payment, you must submit a Claim Form by May 29, 2025.
- Exclude Yourself (Opt-Out): If you wish to retain the right to sue Mylan separately for the claims in this case, you must request exclusion by April 11, 2025. By opting out, you will not receive any payment from this settlement.
- Object to the Settlement: If you disagree with the settlement terms, you can file an objection with the Court by April 11, 2025. If you object, you may still submit a Claim Form to receive a payment if the settlement is approved.
- Do Nothing: If you do nothing and have not previously submitted a claim, you will not receive any payment and will be bound by the settlement’s terms, waiving your right to sue Mylan separately.
Additional Information
For more details, including the full Notice and Settlement Agreement, visit the official settlement website: https://epipendppsettlement.com/Home/MylanHomePage.
If you have questions, contact the Settlement Administrator.
By staying informed and taking timely action, you can protect your rights and potentially receive compensation if you are an eligible direct purchaser affected by this settlement.
